About: Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Creator	Beauverd, Yan Samii, Kaveh Beauverd, Y Samii, Á
Source	PMC
abstract	Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly. Anemia and thrombocytopenia are the main secondary effects. However, there are case reports of rare but serious adverse events following drug withdrawal. We present a case of a 76-year-old man diagnosed with primary myelofibrosis who presented with constitutional symptoms and symptomatic splenomegaly. Ruxolitinib was started (15 mg twice daily) and his disease-related symptoms disappeared. Six weeks later, he developed grade 4 thrombocytopenia and grade 3 anemia. Ruxolitinib was stopped and corticosteroid treatment (prednisone 1 mg/kg/day) was started to avoid a cytokine-rebound reaction. The patient then developed fever, chills, a biological inflammatory syndrome, and an acute respiratory disease syndrome. Full workup excluded an infection and we concluded that ruxolitinib withdrawal syndrome was the likely cause. Continued treatment with corticosteroids, as well as oxygen supply and continuous positive airway pressure, allowed an alleviation of his symptoms. This case report describes acute respiratory distress syndrome as another potential complication of ruxolitinib withdrawal syndrome.
has issue date	2014-07-18(xsd:dateTime)
bibo:doi	10.1007/s12185-014-1628-5
bibo:pmid	25034748
has license	no-cc
sha1sum (hex)	4630ba08005190798faec8547e50d2aabfc0123a
schema:url	https://doi.org/10.1007/s12185-014-1628-5
resource representing a document's title	Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
has PubMed Central identifier	PMC7100122
has PubMed identifier	25034748
schema:publication	Int J Hematol
resource representing a document's body	covid:4630ba08005190798faec8547e50d2aabfc0123a#body_text
is schema:about of	named entity 'Ruxolitinib' named entity 'corticosteroids' named entity 'infection' named entity 'fever' named entity 'withdrawal syndrome' named entity 'ruxolitinib' named entity 'PATIENT' named entity 'BIOLOGICAL' named entity 'DRUG WITHDRAWAL' named entity 'MAIN' named entity 'CASE' named entity 'SYNDROME' named entity 'MAN' named entity 'LATER' named entity 'reaction' named entity 'complication' named entity 'describes' named entity 'acute respiratory distress syndrome' named entity 'started' named entity 'anemia' named entity 'chills' named entity 'Ruxolitinib' named entity 'thrombocytopenia' named entity 'cytokine' named entity 'corticosteroid' named entity 'oxygen' named entity 'fever' named entity 'inflammatory' named entity 'MPL' named entity 'CBC' named entity 'World Health Organization' named entity 'gamma-glutamyltransferase' named entity 'Withdrawal syndrome' named entity 'neoplasm' named entity 'mutation' named entity 'ruxolitinib' named entity 'hypoxemic' named entity 'blood cultures' named entity 'loss of appetite' named entity 'splenomegaly' named entity 'pneumonia' named entity 'hemoglobin' named entity 'lactate dehydrogenase' named entity 'platelet count' named entity 'ARDS' named entity 'constitutional symptoms' named entity 'acute respiratory distress syndrome' named entity 'pegylated interferon' named entity 'essential thrombocythemia' named entity 'JAK2' named entity 'hematopoiesis' named entity 'Biological analysis' named entity 'splenomegaly' named entity 'inflammatory' named entity 'pruritus' named entity 'vasopressors' named entity 'splenomegaly' named entity 'fatigue' named entity 'transfusion' named entity 'lenalidomide' named entity 'cytokine' named entity 'ruxolitinib' named entity 'myelofibrosis' named entity 'blood cell' named entity 'myeloproliferation' named entity 'packed red blood cells' named entity 'splenic infarction' named entity 'computed tomography (CT) scan' named entity 'cytokine' named entity 'sepsis' named entity 'hematology' named entity 'fever' named entity 'quality of life' named entity 'long arm' named entity 'CBC' named entity 'C-reactive protein' named entity 'United States Food and Drug Administration' named entity 'ruxolitinib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software